1-3 of 3
Mark Ray
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US)

Free
Frederick Locke, Bradley Kievit, Genevieve Meier, Rob Blissett, Hil Hsu, Emily Boller, David Cobley, Mark Ray, Olalekan Oluwole
Journal: Blood
Blood (2025) 146 (Supplement 1): 4510.
https://doi.org/10.1182/blood-2025-4510
Published: 2025
Journal Articles

Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma

Free
Sattva Neelapu, Moshe Fridman, Mark Ray, Sally Wade, Jacob Wulff, David Cobley, Jenny Kim, Julio Chavez
Journal: Blood
Blood (2025) 146 (Supplement 1): 3717.
https://doi.org/10.1182/blood-2025-3717
Published: 2025
Journal Articles

Statistical Challenges from Trials of Potentially Curative Treatments: Validation of Cure Assumptions When Analyzing Zuma-7 Follow-up Data of Axi-Cel and Standard of Care Therapy

Free
Anik R Patel, Mark Ray, Yael A Rodriguez-Guadarrama, Nathaniel J Smith, Frank Neumann, Rob Blisset, Allen Xiaodong Xue
Journal: Blood
Blood (2023) 142 (Supplement 1): 6899.
https://doi.org/10.1182/blood-2023-181255
Published: 2023